SAN DIEGO, Nov. 1, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
members of its leadership team will be making presentations at two
high-profile events in November: 31st Annual Meeting &
Associated Programs of the Society for Immunotherapy of Cancer
("SITC") and the Stifel Nicolaus Weisel Healthcare Conference
2016.
31st Annual Meeting of the Society for Immunotherapy of
Cancer (SITC)
Dr. Alain
Algazi, Clinical Instructor, Department of Medicine
(Hematology/Oncology) at the University of
California San Francisco (UCSF), will present an oral poster
presentation for Abstract #466 on November
11, 2016 at 12:50 PM (EST) in
National Harbor, MD. The title of the poster is "Phase II Study of
Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation
in Combination with Pembrolizumab in Stage III/IV Melanoma Patients
with Low Tumor Infiltrating Lymphocytes." The SITC conference
brings together leading scientists, academicians, researchers,
clinicians, government representatives, and industry leaders from
around the world that are dedicated to improving cancer patient
outcomes by advancing the science and application of cancer
immunotherapy. For more information, please visit:
http://www.sitcancer.org/2016.
Dr. Algazi, the Principal Investigator for the Phase II
Investigator Sponsored Trial (IST) led by UCSF, will be presenting
new clinical data from patients treated with a combination of
OncoSec's investigational intratumoral therapy,
ImmunoPulse® IL-12, and Merck's
KEYTRUDA® (pembrolizumab). Patients who had
unresectable metastatic melanoma and were assessed as unlikely to
respond to anti-PD1 monotherapy, were selected to participate in
the Investigator Sponsored Trial (IST). This oral poster
presentation will provide an interim update of 15 treated patients.
Further details on this SITC oral poster presentation will be
provided in upcoming Company communications.
Stifel Nicolaus Weisel Healthcare Conference
2016
OncoSec's CEO, Mr. Punit
Dhillon, will present a corporate overview at the Stifel
Conference on November 15, 2016, at
11:00 AM EST, in New York City.
This conference provides a forum for institutional investors to
connect with senior management and industry experts, and serves as
a showcase for dynamic emerging companies in the healthcare
industry. For more information, please visit:
http://www.stifel.com/institutional/ConferenceAndEvents.
To view the live webcast, please use the following link:
http://wsw.com/webcast/stifel5/oncs. An archived version of the
webcast will be available for 90 days on OncoSec's website:
http://www.oncosec.com.
OncoSec Investor & Analyst Day
In addition,
OncoSec recently announced that it will be hosting its inaugural
Investor & Analyst Day in San
Diego, on November 17, 2016.
The event will be webcast live beginning at 8:00 AM PST. The live webcast can be accessed at:
http://edge.media-server.com/m/p/i6ug66hu, and will be available
for replay on the Company website.
This event will provide a forum for the Company to share updates
on its clinical development plan for melanoma, advancement of its
intratumoral immunotherapy pipeline of DNA-based product
candidates, and next generation device development. For more
information, please visit:
http://ir.oncosec.com/press-releases/detail/1883/oncosec-to-host-investor-analyst-day-on-november-17-2016
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various solid
tumors as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse® IL-12, is currently
in clinical development for several indications, including
metastatic melanoma, head and neck cancer, and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and developing
new immune-targeting agents for use with the ImmunoPulse® platform.
For more information, please visit www.oncosec.com.
CONTACT:
Sophia Ononye,
PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-and-to-host-inaugural-investor-and-analyst-day-in-november-300354589.html
SOURCE OncoSec Medical Incorporated